Core Viewpoint - China Antibody-B (03681) has received approval from the National Medical Products Administration (NMPA) for the clinical trial application (IND) of its first-in-class (FIC) therapeutic product SM17 for treating inflammatory bowel disease (IBD) patients, marking a significant milestone in expanding the treatment scope from atopic dermatitis (AD) to IBD, which includes Crohn's disease (CD) and ulcerative colitis (UC) [1][2] Group 1 - SM17 is a novel humanized IgG4-k monoclonal antibody that targets the IL-25 receptor to modulate type II inflammatory responses, potentially making it a promising treatment candidate for UC [2] - The mechanism of SM17 involves inhibiting IL-25 mediated signaling and downregulating downstream inflammatory cytokines, which distinguishes it from existing single-pathway therapies and offers new treatment options for refractory or complex phenotype patients [2][3] - The company is completing a bridging study to transition SM17 from intravenous to subcutaneous administration, expected to be completed in the first quarter of this year, with plans to initiate a Phase II clinical trial for AD in the second quarter [2] Group 2 - The company views the expansion of SM17's indications from AD to IBD as a significant opportunity to address unmet medical needs in a clinically and commercially valuable area [2][3] - Targeting upstream regulatory factors in the type II inflammatory pathway, such as the IL-25 receptor, supports SM17 as a differentiated, safer, and more effective treatment option for both AD and IBD [3]
中国抗体-B(03681)：SM17用于治疗IBD的IND获NMPA批准